Cost-effectiveness analysis of filgotinib as a first-line treatment for biologic-naive patients with Ulcerative Colitis in Greece
Nomikos, N., Naoum, P., Athanasakis, K. & Kyriopoulos, I.
(2024).
Cost-effectiveness analysis of filgotinib as a first-line treatment for biologic-naive patients with Ulcerative Colitis in Greece.
Value in Health,
27(12, Supplement), S80 - S80.
https://doi.org/10.1016/j.jval.2024.10.419
(2024).
Cost-effectiveness analysis of filgotinib as a first-line treatment for biologic-naive patients with Ulcerative Colitis in Greece.
Value in Health,
27(12, Supplement), S80 - S80.
https://doi.org/10.1016/j.jval.2024.10.419
The aim of this study was to evaluate the cost-effectiveness of introducing filgotinib as a treatment option for patients with moderate to severe Ulcerative Colitis(UC) who are biologic-naïve in Greece compared to adalimumab, golimumab and vedolizumab.